Cargando…
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom
BACKGROUND: Previous studies have demonstrated a substantial economic impact of irritable bowel syndrome (IBS). AIMS: To provide contemporaneous estimates of direct healthcare costs of IBS in the United Kingdom. METHODS: We collected demographic, gastrointestinal and psychological symptoms, quality...
Autores principales: | Goodoory, Vivek C., Ng, Cho Ee, Black, Christopher J., Ford, Alexander C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325446/ https://www.ncbi.nlm.nih.gov/pubmed/35491477 http://dx.doi.org/10.1111/apt.16939 |
Ejemplares similares
-
Impact of Rome IV irritable bowel syndrome on work and activities of daily living
por: Goodoory, Vivek C., et al.
Publicado: (2022) -
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
por: Goodoory, Vivek C., et al.
Publicado: (2022) -
Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome
por: Goodoory, Vivek C., et al.
Publicado: (2022) -
Randomised clinical trial and meta‐analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms and rectal biomarkers of immune activity
por: Castro Tejera, Valeria, et al.
Publicado: (2022) -
The Differences in Prevalence and Sociodemographic Characteristics of Irritable Bowel Syndrome According to Rome II and Rome III
por: Park, Dong Won, et al.
Publicado: (2010)